Abstract 383P
Background
Pancreatic cancer is a highly malignant tumor with a poor prognosis and 5-year survival rate is less than 10%. Surgical resection is the only possible effective means for radical cure of pancreatic cancer. However, the overall survival after radical operation increased from 18 to 26 months while the overall 5-year survival rate was only 5-20%. Therefore, how to stratify patients and predict the prognosis is the important problems to solve in pancreatic cure. We try to obtain the molecular prognosis marker for resectable pancreatic cancer by genes mutation analysis in this study.
Methods
In this study, paired bloods and tissues were collected for investigating the gene variations among 17 patients with pancreatic ductal adenocarcinoma. We selected a panel of 143 clinically relevant cancer genes for targeted sequencing of the whole exons. Freebayes software was used for mutation calling of the samples, and Pearson correlation coefficient was used for gene variations associations between bloods and tissues. The Kaplan-Meier survival analysis was performed for OS and PFS in all patients.
Results
A total of 11,918 gene variations was shared by both the tissues and bloods. The gene mutation frequency was consistent between tissues and bloods with Pearson correlation coefficient of 0.99. We selected 62 genes in tissues and 35 genes in bloods annotated with the pathogenesis relevant gene variation for further analysis. In total, 35 of 62 genes identified in tissues were detected in bloods where 85 of 120 gene variations in bloods were found in tissues. KRAS, TP53, BRCA2, PTPN11 and TSC2 were the most common mutated genes detected in the tissues, and BRCA2, BRCA1, TERT, TP53 were the most common mutated genes in bloods. The Kaplan-Meier survival analysis found that ATM-BRCA1 and BRCA2 mutation had a poorer prognosis.
Conclusions
In the study, mutations in 143 cancer related genes of paired bloods and tissues in 17 patients were detected and three mutation genes could be the diagnostic biomarker for verification in the future. We also revealed the consistency of gene mutations between the tissues and bloods to some extent. Our results provide the reference for cancer detection and treatment for resectable pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Geneis Co. Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract